Talking About External Genital and Perianal Warts With Your Patients

Let's Talk
External Genital and Perianal Warts (EGW)

Scroll Down

Photo for illustrative purposes only. Not actual patient.

Almost everyone who has sex can get external genital and perianal warts (EGW)

About 1 in 100 SEXUALLY
ACTIVE

ADULTS HAS EGW

Photo for illustrative purposes only. Not actual patients.

A diagnosis of EGW often evokes feelings of shame, embarrassment, anger, and fear

Photo for illustrative purposes only. Not actual patients.

Making the conversation about EGW uncomfortable for both you and your patients.

Photo for illustrative purposes only. Not actual patients.

Putting patients at ease starts with an open and honest discussion with you

Photo for illustrative purposes only. Not actual patients.

While resources like veregen.com are here to support you.

Scroll Down

Photo for illustrative purposes only. Not actual patient.

Here's What Patients Want to Hear Directly From You About EGW

They're not dangerous

The strains of HPV that cause EGW are low-risk HPV strains that do not cause cancer.1,2

They can be asymptomatic

Although for some patients EGW can be very obvious, for others they can be asymptomatic, so patients may unknowingly transmit the viruses that cause EGW.1,3

They may take time to appear

EGW may appear weeks or months after acquiring an HPV infection. Or they may never appear, making it difficult to know exactly when or from whom a person contracted EGW.1,3

They are sexually transmitted

Using a condom during sex may help reduce the risk of getting HPV, but a condom does not always cover all the affected skin—so it may not completely protect your patient and his or her partner.1

They can be treated

Treatment may help alleviate the symptoms of EGW, although treatment does not cure the HPV infection itself, and recurrence is common.1

Photo for illustrative purposes only. Not actual patient.

CDC Recommends Incorporating "The 5 'Ps' of Sexual Health" Into the Conversation4

Partners

Photo for illustrative purposes only. Not actual patients.

Partners

Ask about number of partners and risk factors of those partners.4

Practices

Photo for illustrative purposes only. Not actual patients.

Practices

Encourage patients to practice safe sex, such as abstinence, monogamy, and condom use.1,4

Protection from STDs

Protection from STDs

Identify risk factors for STDs and try to determine the patient's perception of his or her own risk as well as his or her partner's risk.4

Past history of STDs

Past history of STDs

Inquire about testing for STDs and assess history of STDs.4

Prevention of pregnancy

Prevention of pregnancy

Determine risk of becoming pregnant or fathering a child; counsel accordingly, including offering information on birth control or making a referral if appropriate.4

Additional information from your patients may be needed, but "The 5 Ps" may lay the foundation for an open and honest dialogue about sexual health.

VEREGEN® (sinecatechins) Can Help Clear EGW Infection

Low discontinuation rate and a low adverse event profile

Only 2.3% of VEREGEN® patients discontinued treatment due to local adverse events.5

The majority of adverse events were mild or moderate local application site reactions.6 In the overall study population, the maximum mean severity of erythema, erosion, edema, and induration was observed by week 2 of treatment.7

Clearance rates of EGW*

Complete Clearance

picture of pie chart

(vs 35.3% for vehicle)7

Sustained Clearance

picture of pie chart

(vs 94.2% for vehicle) at 12 weeks post treatment7

*The effectiveness of VEREGEN® was assessed in two phase 3, randomized, double-blind, vehicle-controlled studies (United States and international) of immunocompetent male and female patients (N=604) aged 18 years and older who had EGW. VEREGEN® or vehicle was applied 3 times daily until complete clinical (visual) clearance of all EGW (baseline and new) or up to 16 weeks. Those patients who experienced complete clearance of all warts were followed for a 12-week, treatment-free period to assess sustained clearance.6,7

Request VEREGEN® Samples

Request VEREGEN® Samples

It's easy to get samples of VEREGEN® ointment. Simply complete the form and fax it back.

Patient Savings for VEREGEN®

The PharmaDerm RxSAVER PROGRAM can help eligible patients save on their VEREGEN® copays.

The program requires patient enrollment. Instruct patients to visit PharmaDerm.com to enroll in the program.

picture of co-pay icon

Eligibility and restrictions: 1. Limitations apply. 2. Valid only for those with commercial insurance. 3. Not valid if prescriptions are paid in part or in full by any state or federally-funded healthcare program. 4. Not valid for cash-paying patients who have no commercial insurance or where plan reimburses you for the entire cost of your prescription drug. 5. Offer is not valid where prohibited by law. 6. Valid only for residents of the US and Puerto Rico. 7. This program is not health insurance. 8. Offer may not be combined with any other rebate, coupon, or offer. 9. This card is the property of PharmaDerm, a division of Fougera Pharmaceuticals Inc. and must be returned upon request. 10. Fougera reserves the right to rescind, revoke, or amend the program without notice. 11. Patient certifies responsibility for complying with applicable limitations, if any, or any commercial insurance and reporting receipt of program rewards, if necessary, to any commercial insurer. 12. Acceptance of this card and your submission of claims for the PharmaDerm RxSaver Program are subject to the Terms and Conditions established by TrialCard® Inc. 13. This card has no cash value. 14. This Offer expires on December 31, 2019. For any questions regarding set up, claims transmission, patient eligibility or other issues, call the PharmaDerm RxSaver Program at 1-844-396-8097 (24 hrs Monday-Friday, 8AM-7PM Saturday, 9AM-5PM Sunday EST).

Dealing with EGW may take more than just treatment

Emotional and Educational Support for Your Patients

Important Safety Information

VEREGEN® (sinecatechins) has not been evaluated to treat urethral, intra-vaginal, cervical, rectal, or intra-anal human papilloma viral disease and should not be used to treat these conditions. Avoid use of VEREGEN® on open wounds.

Avoid exposure of VEREGEN®-treated areas to sun/UV-light because VEREGEN® has not been tested under these circumstances. Safety and efficacy of VEREGEN® have not been established in immunosuppressed patients or patients under 18 years of age, or pregnant women, or for the treatment of external genital and perianal warts beyond 16 weeks or for multiple treatment courses.

The most common adverse reactions are local skin and application site reactions including (incidence ≥20%) erythema, pruritus, burning, pain/discomfort, erosion/ulceration, edema, induration, and rash vesicular.

Please see Full Prescribing Information for VEREGEN®.

You are encouraged to report negative side effects of prescription drugs to the Food and Drug Administration (FDA). Please visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Indication

VEREGEN® is indicated for the topical treatment of external genital and perianal warts (Condylomata acuminata) in immunocompetent patients 18 years and older.

References: 1. Genital HPV infection. CDC Fact Sheet. Centers for Disease Control and Prevention website. https://www.cdc.gov/std/hpv/HPV-FS-July-2017.pdf. Accessed April 16, 2019. 2. Genital warts: overview. American Academy of Dermatology website. https://www.aad.org/public/diseases/contagious-skin-diseases/genital-warts. Accessed April 15, 2019. 3. Genital warts. Centers for Disease Control and Prevention website. https://www.cdc.gov/healthcommunication/toolstemplates/entertainmented/tips/GenitalWarts.html. Accessed April 17, 2019. 4. A guide to taking a sexual history. Centers for Disease Control and Prevention website. https://www.cdc.gov/std/treatment/SexualHistory.pdf. Published 2011. Updated March 14, 2014. Accessed April 15, 2019. 5. Data on file, Fougera. 6. Stockfleth E, Beti H, Orasan R, et al. Topical Polyphenon® E in the treatment of external genital and perianal warts: randomized controlled trial. Br J Dermatol. 2008;158(6):1329-1338. 7. VEREGEN® Ointment, 15% [prescribing information, Rev. 2018]. Melville, NY: PharmaDerm, a division of Fougera Pharmaceuticals Inc.